Oncology

The AACR roadmap spotlights LDCT screening, ctDNA MRD monitoring, and new NSCLC/SCLC therapies like DLL3 tarlatamab to close survival gaps.

County-level CRC mortality was higher in areas with limited broadband access, higher smoking rates, and rurality.

Intismeran autogene plus pembrolizumab significantly improved recurrence-free and distant metastasis-free survival compared with pembrolizumab alone in resected stage IIB-IV melanoma.

Fecal immunochemical tests (FITs) generate substantially fewer emissions than colonoscopy or CT colonography, driven largely by transportation.

The increasingly complex CLL treatment landscape will require continued real-world study to guide sequencing decisions.

A gene tied to poor sarcoma prognosis also rose fastest in pazopanib-sensitive sarcoma cell lines, a new exploratory study suggests.

Genetic ancestry was linked to differences in colorectal cancer (CRC) burden and age-specific risk, with implications for screening.

It also flagged persistent gaps in biomarker testing and the limits of cross-trial comparisons for treatment selection.

July AJMC author Anuraag R. Kansal, PhD, explains how metastatic cancer diagnoses drive Medicaid spending and why earlier screening could lower costs.

All from July, these 5 novel therapeutics each claimed a “first” in their category.

Phase 3 SOLARIS found high-dose vitamin D3 added to standard chemotherapy did not significantly improve progression-free survival in metastatic CRC.

OpenEvidence plugs into OneOncology tools, delivering fast oncology evidence, genomic context and clinical-trial matches at the point of care.

Peter Forsberg, MD, discusses referral pathways, payer barriers, and expanding access to CAR T-cell and bispecific therapies.

Novartis says it can deliver doses to treatment sites with 5 days of order.

Panelists emphasized coordinated care, biomarker testing, innovative therapies, and clinical trial access to advance precision oncology.

New data suggest acalabrutinib appears to reduce the target that macrophages are supposed to recognize in patients with CLL.

An unanswered question: will an additional 7 minutes translate into fewer postcolonoscopy cancers and lower downstream costs?

These findings reinforce that matching therapy intensity and type to genetic and treatment-history profile is likely to be the next lever for improving outcomes.

A study found that elevated IL-6 and IL-17A levels were associated with greater fatigue for up to 3 years after CRC diagnosis.

Panel experts at Nashville’s IVBM event discussed matching cancer therapy intensity to disease, easing access barriers, and reforming pharmacy/PBM policies.

A July AJMC study found metastatic cancer diagnoses significantly increase Medicaid spending, highlighting the potential budget benefits of earlier detection.

Denise Yardley, MD, on OPTIMA, Prosigna proliferation scoring, and telling patients an endocrine strategy fits how their tumor behaves.

Experts discussed biomarker testing, novel cancer therapies, multidisciplinary care, and strategies to expand access.

Vicki Keedy, MD, speaks to sarcoma research funding gaps, delayed diagnosis, and why the European specialty center model outperforms US referral patterns.

Navista names Jeff Hunnicutt COO, bringing in a well-known oncology leader with experience in technology and innovation at the practice level.